First-pass extracted concept

gene editing technologies for cardiovascular disease

Candidate: concept label1 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

The review describes gene editing technologies as approaches to correct pathogenic variants and modulate disease pathways in cardiovascular disease.

Source 1DOI PubMed

Resources required

The abstract indicates that successful use depends on delivery systems and gene-editing enzymes, with attention to vector engineering and tissue-selective delivery.

Source 1DOI PubMed

What problem it solves

It addresses the need for durable genomic therapies for cardiovascular disorders.

Source 1DOI PubMed

What it does not solve

The abstract states that delivery inefficiency, imprecision, immunogenicity, and toxicity are not yet fully solved.

Source 1DOI PubMed

Alternatives

The abstract contrasts gene editing with existing pharmacological, device, and surgical care rather than naming specific alternative editing modalities.

Source 1DOI PubMed

Evidence Snippets

Gene editing technologies have introduced a transformative approach to correct pathogenic variants and modulate disease pathways.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1application potentialsupports2026Source 1DOI PubMed

Gene editing technologies are presented as a transformative approach for correcting pathogenic variants and modulating disease pathways in cardiovascular disease.

Claim 2scope expansionsupports2026Source 1DOI PubMed

Next-generation editors and targeted delivery systems have expanded the scope of feasible cardiovascular applications, but biological barriers still limit translation to well tolerated durable one-time genomic therapies.

Claim 3technical barriersupports2026Source 1DOI PubMed

Emerging editing technologies aim to overcome limited vector cargo capacity, PAM incompatibility, chromatin accessibility, suboptimal editing efficiency, and off-target activity.

Claim 4translation constraintsupports2026Source 1DOI PubMed

Successful clinical translation of gene and base editing for cardiovascular disease depends on efficient and precise delivery and on mitigating immunogenicity and toxicity from both delivery vectors and gene-editing enzymes.